SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing fully human, multi-targeted, high-potency immunoglobulins (IgGs) without human donors or convalescent plasma to treat and prevent immune and autoimmune disorders. Its lead asset, SAB-142, targets type 1 diabetes with a disease-modifying approach. Using advanced genetic engineering, the company developed Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, enabling the DiversitAb system to produce diverse, high-potency, fully-human IgGs for various unmet medical needs. The SABS average annual return since 2021 is shown above.
The Average Annual Return on the SABS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SABS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SABS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|